Buscar.
Resultados de la búsqueda 12
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China) Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration）approved AmoyDx Super-ARMS® EGFR mutation test kit
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
Super-ARMS® EGFR Mutation Detection Kit
The best solution for Plasma EGFR Mutation Testing
PRODUCTOS
no más...
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China) Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685) announced that NMPA（National Medical Products Administration）approved AmoyDx Super-ARMS® EGFR mutation test kit
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
no más...